ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Takeda announces results of Phase 3b VARSITY studies biospectrumasia
May 20, 2019VARSITY is a Phase 3b, randomized, double-blind, double-dummy, multi-center, active-controlled study to evaluate the efficacy and safety of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) at week 52 in patients with moderately to sev
Pharma Sources Insight January 2025
